Non Small Cell Lung Carcinoma Nsclc clinical trials

Explore recruiting non small cell lung carcinoma nsclc clinical trials.

Recruiting non small cell lung carcinoma nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Small Cell Lung Carcinoma Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, locally advanced, unresectable or metastatic PD-L1 selected non small cell lung cancer (GALAXIES LUNG 301)

Italy, Belgium, Romania, Portugal, Netherlands, Finland +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

Spain, Netherlands, Germany, France, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

ADP-A2M4CD8 in advanced cancers

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

INTERVENTIONAL PLATFORM STUDY INVESTIGATING THE IMPACT OF DIGITAL HEALTH SOLUTIONS ON HEALTH OUTCOMES AND HEALTH-CARE RESOURCE UTILIZATION IN PARTICIPANTS RECEIVING SYSTEMIC TREATMENT IN CLINICAL PRACTICE (ORIGAMA)

Austria, Spain, Germany

Phase II and Phase III (Integrated) EU CTIS Study details

LAG3 PET; ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with or without platinum-based chemotherapy

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Small Cell Lung Carcinoma Nsclc trials by city

Non Small Cell Lung Carcinoma Nsclc in Toronto Non Small Cell Lung Carcinoma Nsclc in Vancouver Non Small Cell Lung Carcinoma Nsclc in Montreal Non Small Cell Lung Carcinoma Nsclc in Calgary Non Small Cell Lung Carcinoma Nsclc in Edmonton Non Small Cell Lung Carcinoma Nsclc in Ottawa Non Small Cell Lung Carcinoma Nsclc in Winnipeg Non Small Cell Lung Carcinoma Nsclc in Quebec City Non Small Cell Lung Carcinoma Nsclc in Hamilton Non Small Cell Lung Carcinoma Nsclc in Kitchener Non Small Cell Lung Carcinoma Nsclc in London Non Small Cell Lung Carcinoma Nsclc in Halifax Non Small Cell Lung Carcinoma Nsclc in New York Non Small Cell Lung Carcinoma Nsclc in Los Angeles Non Small Cell Lung Carcinoma Nsclc in Chicago Non Small Cell Lung Carcinoma Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease